09/787560 532 Rec CT. TTO 19 MAR 2001

Sheet <u>1</u> of <u>1</u>

Form PTO-1449 (Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 720797.90019 SERIAL NO. 09/787560

INFORMATION DISCLOSURE STATEMENT BY APPLICANT					TEMENT	APPLICANT Christopher M. Dobson					
		(Us	e several she	ı	FILING DA	_{те} h 19, 20	001	GROUP	H7		
		100	<u> </u>		ATENT DOCUMENTS					<u>, , , , , , , , , , , , , , , , , , , </u>	
* EXAMINER'S INITIAL		DOCUMENT NUMBER		DATE	NAME		CLASS SUBCLASS		CLASS	FILING DATE IF APPROPRIATE	
(S)		4,66	66,829	05/19/87	G. Glenner et al.						
490		5,17	71,574	12/15/92	T. Kuberasampath	et al.					
											
				FOREIGN	PATENT DOCUMENTS	s					
		pocu	MENT NUMBER	DATE	COUNTRY		CLASS	SUBCLA	vss	TRANSLA YES	TION
رى	-	wos	7/15195	05/01/97	PCT			_			Х
8		wos	7/15933	05/01/97	РСТ						X
											ļ
 		 									
	-										<u> </u>
S			S. Malinch	nik <u>et al.</u> , Struc	<i>ng Author, Title, Date,</i> itural Analysis Of Alz rils; 74 J. Biophys. 5	heimer'	s β(1-40)		loid: I	Protofila	nent
			E. Castaño Of Differe	o <u>et al.,</u> In Vitro nt Lengths Hor	o Formation Of Amyl mologous To Alzheim n. 782-789 (1986)	loid Fibr	ils From				
	D. Kirschner et al.; Synthetic Peptide Homologous to β Protein From Alzheimer Disease Forms Amyloid-like Fibrils <i>in vitro</i> ; 84 Proc. Natl. Acad. Sci. USA 6953-6957 (1987)										
1		<u> </u>	L. Tjernberg <u>et al.</u> ; Controlling Amyloid β-Peptide Fibril Formation With Protease-stable Ligands 272 J. Biolog. Chem. 12601-12606 (1997)								
(B)		J. Guijarro et al.; Amyloid Fibril Formation By An SH3 Domain; 95 Proc. Natl. Acad. Sci. USA 4224-4228 (1998)									
EXAMINER	6	<u> </u>	ile	3	DATE CONSIDERED	71	7/02		-		· · ·
* EXAMINER conformand KE\5021172					citation is in conformance n with next communication			w line th	rough	citation if	not in



Sheet <u>1</u> of <u>1</u>

Form PTO-1449 (Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 720797.90019 SERIAL NO. 09/787,560

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

APPLICANT Christopher M. Dobson

	(Us	se several she	eets if necessary)		March 19, 2	001 GAO	1647			
			U.S. P	ATENT DOCUMENTS						
* EXAMINER'S DOCUME		UMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
				PATENT DOCUMENT						
	DOCU	JMENT NUMBER	DATE COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO				
		· · ·	OTHER DOCUMENTS (Inc	cluding Author, Title, Date, Pertinent	Pages, Etc.)					
(3) -		J. Campistol et al., Polymerization Of Normal And Intact β2-microglobulin as the Amyloidogenic Protein in Dialysis-amyloidosis; 50 J. Kidney International 1262-1267 (1996)								
			., Alternative Confo Biology 11-17 (19	ormations Of Amyloidogeni 96)	c Proteins Govern Tl	heir Behavior;	6 Current Opinion			
-	-			Of Kappa And Lambda Lig		d Filaments O	f Dialysis-Related			
' -	-	C. Shen <u>et</u> a	I., Solvent Effects (On Self-Assembly Of β-Am	yloid Peptide; 69 Bio	ophysical Jour	nal 640-651			
-	 -	S. Tan et al., Amyloidosis; 25 Histopathology 403-414 (1994)								
-	,	F. Tagliavini <u>et al.,</u> Synthetic Peptides Homologous To Prion Protein Residues 106-147 Form Amyloid-like Fibrils in Vitro 90 PNAS USA 9678-9682 (1993)								
		T. Stenstad et al., On The Association Between Amyloid Fibrils And Glycosaminoglycans; Possible Interactive Role Of Ca2 + And Amyloid P-component, 94 Clin. Exp. Immunol 189-195, (1993)								
_	D. Kirschner et al., Synthetic Peptide Homologous To β Protein From Alzheimer Disease Forms Amyloid-like Fibrils In Vitro; 84 PNAS. USA 6953-6957 (1987)									
	E. Castono et al., In Vitro Formation Of Amyloid Fibrils From Two Synthetic Peptides Or Different Lengths Homologous To Alzheimer's Disease β-protein; 141 Biochemical And Biophysical Research Communications 782-789 (1986)									
) -	C. Dobson et al., Protein Folding And Misfolding Inside And Outside The Cell; 17 The EMBO Journal 5251-5254 (1998)									
· -	C. Dobson et al., Folding And Binding From Theory To Therapy; 7 Current Opinion In Structural Biology 1-2 (1997)									
_	•	D. Booth et al., Instability, Unfolding And Aggregation Of Human Lysozyme Variants Underlying Amyloid Fibrillogenesis; 385 Nature 787-793 (1997)								
		L. Smith et al., The Concept Of A Random Cell Residual Structure In Peptides And Denatured Proteins; 1 Folding And Design \$95-R106 (1996)								
V	<u> </u>	S. Radford et al., From Computer Simulations To Human Disease: Emerging Themes In Protein Folding; 97 Cell 291-298 (1999)								
CBN -	L. Smith et al., Analysis Of Main Chain Torsion Angles In Proteins: Prediction Of NMR Coupling Constants For Native And Random Coil Conformations; 255 J. Mol. Biol. 494-506 (1996)									
EXAMINER	1	11-	12	DATE CONSIDE	RED 111	102				

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MKE\5021172

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.
U.S. Patent and Trademark C ffice: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information units it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Comp. ate if Known							
Application Number	09.787,560						
Filing Date	Ma.ch 19, 2001/June 4, 2001						
First Named Inventor	Chr stopher M. Dobson						
Group Art Unit	164						
Examiner Name	Sar ara L. Wegert NICHOCS						
Attorney Docket Number	720797 90019						

	U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.1	U.S. Paten Number	t Document Kind Code ² (if known)	of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
						RECEIVED			
						JAN 2 4 2003			
					TE(CH CENTER 1600/2900			

	FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No. ¹	Foreign Patent Document Office³ Number⁴ Kind Code⁵ (if known)		Kind Code ⁵ Name of Patentee or Cite Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te		
(D)		wo	97/07402		Chakrabartty	02-27-1997				
	-							1		
				-				1 1		
<u> </u>		<u> </u>						\square		
								\Box		
						1				

Examiner	11/11/11	Date	2/2/02
Signature	SULLOS	Considered	7/105

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include one of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MKE\5357349

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.